Attenuation of Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) Rats with a Combination of Chinese Herbs (Tangshen Formula)

Diabetic nephropathy is one of the most significant microvascular complications in patients with type 2 diabetics. The concise mechanism of diabetic nephropathy is unknown and there is no successful treatment. The objective of study was to investigate effects of Chinese herbs (Tangshen Formula) on diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. OLETF rats and LETO rats were divided into four groups: LETO control, OLETF diabetics, OLETF diabetics treated with Tangshen Formula, and OLETF diabetics treated with Monopril. Body weight, blood glucose, and 24 h urinary proteins were measured once every four weeks. Blood samples and kidney tissues were obtained for analyses of total cholesterol, triglyceride, whole blood viscosity, plasma viscosity, and pathohistological examination at 36 and 56 weeksrespectively. Untreated OLETF rats displayed diabetic nephropathy over the study period. Treatment of OLETF rats with Tangshen Formula attenuated the increases in blood glucose, body weight, 24 h urinary protein content, serum total cholesterol, whole blood viscosity and plasma viscosity at certain time. Treatment with Tangshen Formula also reduced glomerulosclerotic index and interstitial fibrotic index seen in OLETF rats. In conclusion, Tangshen Formula could attenuate the development of diabetic nephropathy in OLETF rat diabetic model.

[1]  Y. Wan,et al.  [Mechanism of Chinese herbal medicine delaying glomerulosclerosis in diabetic nephropathy]. , 2010, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[2]  A. Mahdi,et al.  Lipid Lowering Activity of Anthocephalus indicus Root in Hyperlipidemic Rats , 2008, Evidence-based complementary and alternative medicine : eCAM.

[3]  Hyunsu Bae,et al.  Evidence Based Complementary and Alternative Medicine , 2008, Evidence-based complementary and alternative medicine : eCAM.

[4]  Xiao-hui Li,et al.  PANAX NOTOGINSENG SAPONINS ATTENUATE ATHEROSCLEROSIS IN RATS BY REGULATING THE BLOOD LIPID PROFILE AND AN ANTI‐INFLAMMATORY ACTION , 2008, Clinical and experimental pharmacology & physiology.

[5]  K. Kalantar-Zadeh,et al.  Glycemic control in diabetic CKD patients: where do we stand? , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Song-min Huang,et al.  [Expression of VEGF in kidney of diabetic rats]. , 2007, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[7]  G. Wolf,et al.  Cellular and Molecular Mechanisms of Proteinuria in Diabetic Nephropathy , 2007, Nephron Physiology.

[8]  T. Coffman,et al.  The renin-angiotensin system and diabetic nephropathy. , 2007, Seminars in nephrology.

[9]  M. Cooper,et al.  Diabetic nephropathy: where hemodynamics meets metabolism. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  P. Rossing.  Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history , 2006, Current diabetes reports.

[11]  J. Mehta,et al.  Oxidative stress in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. , 2006, The international journal of biochemistry & cell biology.

[12]  R. Trevisan,et al.  Lipids and renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[13]  Sunmin Park,et al.  Insulin sensitizing and alpha-glucoamylase inhibitory action of sennosides, rheins and rhaponticin in Rhei Rhizoma. , 2006, Life sciences.

[14]  D. Churchill,et al.  Effect of chronic kidney disease on red blood cell rheology. , 2006, Clinical hemorheology and microcirculation.

[15]  Z. Fan.  A survey of treatment of diabetic complications with Chinese drugs. , 2005, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[16]  G. Wolf,et al.  From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. , 2005, Diabetes.

[17]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[18]  R. Bilous,et al.  Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes , 1992, Pediatric Nephrology.

[19]  G. Jerums,et al.  The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  E. Vivian,et al.  Pharmacologic management of diabetic nephropathy. , 2002, Clinical therapeutics.

[21]  J. Chan,et al.  Management of nephropathy in patients with type 2 diabetes. , 2002, Chinese medical journal.

[22]  M. Cooper,et al.  Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. , 2000, Diabetes & metabolism.

[23]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[24]  S. Shin,et al.  Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo. , 2000, The Journal of laboratory and clinical medicine.

[25]  H. Iwao,et al.  Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes. , 1999, Life sciences.

[26]  B. Levine,et al.  Stress produced by gavage administration in the rat. , 2000, Contemporary topics in laboratory animal science.

[27]  K. Kawano,et al.  Examination of the pathogenesis of diabetic nephropathy in OLETF rats. , 1999, The Journal of veterinary medical science.

[28]  A. Fujimura,et al.  HYPERLIPIDAEMIA AND THE PROGRESSION OF NEPHROPATHY IN OLETF RATS: EFFECT OF ANGIOTENSIN‐CONVERTING ENZYME INHIBITOR, ENALAPRIL , 1999, Clinical and experimental pharmacology & physiology.

[29]  V. Chábová.  [Pathophysiology of diabetic nephropathy]. , 1999, Casopis lekaru ceskych.

[30]  E. Humble,et al.  Hepatic cholesterol metabolism in experimental nephrotic syndrome , 1998, Lipids.

[31]  C. Wanner,et al.  Potential role of lipids in the progression of diabetic nephropathy. , 1996, Clinical nephrology.

[32]  S. Freytag,et al.  Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. , 1995, The Journal of clinical investigation.

[33]  M. Lishner,et al.  Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. , 1995, Kidney international.

[34]  J. Ménard,et al.  Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. , 1994, Kidney international.

[35]  K. Kawano,et al.  Spontaneous Long-Term Hyperglycemic Rat With Diabetic Complications: Otsuka Long-Evans Tokushima Fatty (OLETF) Strain , 1992, Diabetes.

[36]  H J Bilo,et al.  Blood and plasma viscosity in diabetes: possible contribution to late organ complications? , 1992, Diabetes research.

[37]  G. Neild,et al.  Blood Hyperviscosity and Its Relationship to Progressive Renal Failure in Patients with Diabetic Nephropathy , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[38]  G. Neild,et al.  Abnormal blood rheology in progressive renal failure: a factor in non-immune glomerular injury? , 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.